Sosei Heptares and PharmEnable collaborate on neurological drug research

pharmafile | January 12, 2021 | News story | Manufacturing and Production PharmEnable, Sosei Heptares 

Sosei Group Corporation and PharmEnable, a UK drug discovery company, have joined forces to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.

The collaboration will combine Sosei Heptares’ GPCR-focused structure-based drug design platform – which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability – with PharmEnable’s proprietary advanced artificial intelligence-enabled and medicinal chemistry technologies to identify novel, highly specific drug leads for further development.

The UK company’s approach identifies three-dimensional drug candidate hits with improved specificity compared with traditional screening methods, and allows the company to take on particularly challenging biological targets, such as peptidergic GPCRs, which have proved difficult to drug using existing approaches.

The natural agonist ligand of a peptidergic GPCR is a large, complex peptide and is often very difficult to block with a small molecule, particularly one that has properties suitable for development as a therapeutic agent for neurological disease.

Under the agreement, the companies will jointly conduct and share the costs of the discovery and development program and will co-own any resulting products. No further financial details have been disclosed.

Miles Congreve, Chief Scientific Officer of Sosei Heptares, said: “We have been very impressed with PharmEnable’s technology and approach, which we believe to be highly complementary to our own, offering important synergies for drug discovery on challenging GPCR targets. We are excited to apply these technologies on a peptidergic GPCR target that has proved particularly difficult to drug.

“We have so far assembled a wealth of structural and ligand-binding information on the target and created several promising molecules but have yet to identify compounds with sufficiently desirable neurological drug-like properties to advance into preclinical studies. Combining our respective technologies and expertise may be the key that unlocks this target and enables the identification of higher quality molecules to progress into preclinical development.”

Hannah Sore, Chief Executive Officer of PharmEnable, added: “We are excited to partner with Sosei Heptares on this challenging and complex GPCR target. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets.

“Combining our platform with the technology and structural insights developed by Sosei Heptares should enable us to generate several potential hits, and to establish our pipeline of candidate molecules for the treatment of challenging diseases.”

Darcy Jimenez

Related Content


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …


Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial

Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed …


Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

Sosei Heptares has announced that it has dosed its first patient in its phase 1 …

Latest content